Geode Capital Management LLC Sells 20,126 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Geode Capital Management LLC decreased its stake in shares of OptimizeRx Co. (NASDAQ:OPRX) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 395,800 shares of the company’s stock after selling 20,126 shares during the period. Geode Capital Management LLC owned 2.16% of OptimizeRx worth $3,056,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets lifted its position in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. Connors Investor Services Inc. lifted its holdings in OptimizeRx by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Rhumbline Advisers lifted its holdings in OptimizeRx by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after purchasing an additional 2,658 shares during the last quarter. Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 8.0% in the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after buying an additional 4,999 shares in the last quarter. Finally, Quest Partners LLC increased its position in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Trading Up 1.5 %

NASDAQ OPRX opened at $5.57 on Tuesday. The company has a market cap of $102.60 million, a price-to-earnings ratio of -4.19 and a beta of 1.36. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The business’s fifty day moving average is $5.15 and its 200 day moving average is $7.31.

Insider Buying and Selling

In other news, CEO William J. Febbo bought 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

OPRX has been the subject of a number of recent research reports. Roth Mkm reissued a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Stifel Nicolaus cut their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Stephens initiated coverage on shares of OptimizeRx in a report on Friday, December 20th. They set an “equal weight” rating and a $5.50 target price on the stock. Royal Bank of Canada dropped their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, Lake Street Capital reissued a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research report on Tuesday, December 24th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.19.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.